A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors

Trial Profile

A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs MEDI 4276 (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Male breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 21 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2018 This trial has been completed in Spain (end date: 2018-05-23)
    • 24 Apr 2018 Planned End Date changed from 1 Oct 2019 to 6 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top